Delta-8 THC: What It Is, What the Research Shows, and Why Its Legal Status Is Changing
Delta-8 tetrahydrocannabinol, commonly called delta-8 THC, is a psychoactive cannabinoid related to delta-9 THC—the compound primarily responsible for cannabis’s intoxicating effects. It occurs naturally in cannabis, but usually only in very small amounts. Most commercial delta-8 products are made by converting hemp-derived cannabidiol (CBD) into concentrated delta-8 THC.
Delta-8 products became widely available in the United States after the 2018 Farm Bill defined hemp using a limit on delta-9 THC rather than on all intoxicating cannabinoids. That wording created an opening for products containing delta-8 THC to be marketed as hemp-derived, although the interpretation has been disputed by federal agencies, courts, state regulators and industry groups.
The chemistry of delta-8 THC is similar to that of delta-9 THC, but the two compounds are not identical. A 2022 pharmacology review found that both interact with the brain’s CB1 cannabinoid receptor and produce similar types of effects. Delta-8 appeared to be less potent in the limited human studies available, likely because it binds less strongly to CB1 receptors. That does not make it non-intoxicating or risk-free.
Newer clinical evidence supports a more cautious version of the commonly reported “milder high” claim. In a 2025 randomized crossover trial of 19 healthy adults, oral delta-8 THC produced effects similar to delta-9 THC, while equivalent doses of delta-9 generally produced stronger subjective effects. The study was small and examined short-term effects in healthy volunteers; it did not establish that delta-8 causes less anxiety, is safer, or is an effective treatment for any medical condition.
Claims that delta-8 THC is antiemetic, anxiolytic, appetite-stimulating, analgesic or neuroprotective should therefore be treated as preliminary. Some findings come from older studies, animal experiments, laboratory research or self-reported user surveys rather than well-controlled clinical trials. A 2023 scoping review concluded that much of the available evidence remains anecdotal, focused on animals or cells, or concerned with identifying delta-8 in commercial products. There is not enough high-quality human evidence to support marketing delta-8 as a proven therapy.
Product quality is another concern. Because concentrated delta-8 is commonly manufactured from CBD through chemical conversion, the final product may contain reaction by-products, residual solvents, other cannabinoids or inaccurately measured doses. Manufacturing and testing standards have not been consistent across the market. Products sold as gummies, candies, beverages, vape cartridges and other familiar consumer goods may also be mistaken for ordinary hemp products or accidentally consumed by children.
The Food and Drug Administration warns that delta-8 products have not been evaluated or approved for safe use and has reported adverse-event reports involving hallucinations, vomiting, tremor, anxiety, dizziness, confusion and loss of consciousness. The agency has also raised concerns about pediatric exposures, appealing packaging, misleading therapeutic claims and contaminants created during manufacturing. Delta-8 products should be kept away from children and pets, and consumers should not assume that “hemp-derived” means non-intoxicating or FDA-approved.
Federal law is also in transition. The 2018 framework remains the source of the original controversy, but the amended federal hemp definition enacted in 2025 is scheduled to take effect on November 12, 2026. It changes the focus from delta-9 THC alone to total THC and excludes certain products containing synthetically manufactured cannabinoids, as well as final products exceeding specified limits for total THC and similar intoxicating cannabinoids. Until those provisions take effect, and as regulators interpret and implement them, the federal treatment of particular delta-8 products can depend on how they were made, what they contain and how they are sold. State laws vary considerably.
Delta-8 THC is best understood as an intoxicating cannabis compound with a potentially lower average potency than delta-9 THC—not as a harmless or established wellness ingredient. Its effects may be milder for some users, but the evidence remains limited, commercial products can be inconsistent, and the legal landscape is changing. The most reliable conclusions at present concern the need for accurate labeling, contamination controls, age restrictions and better human research.
